Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 NEDD4: a promising target for cancer therapy.

Literature DB >> 25088038

NEDD4: a promising target for cancer therapy.

Xiantao Ye, Lixia Wang, Bingxue Shang, Zhiwei Wang, Wenyi Wei¹.

Abstract

The Neuronally expressed developmentally downregulated 4 (NEDD4), functioning largely as an E3 ubiquitin ligase, has been demonstrated to play a critical role in the development and progression of human cancers. In this review, to understand the regulatory mechanism(s) of NEDD4 as well as the signaling pathways controlled by NEDD4, we briefly describe the NEDD4 upstream regulators and its downstream ubiquitin substrates. Moreover, we further discuss its oncogenic roles in human malignancies. Therefore, targeting NEDD4 could be a potential therapeutic strategy for treatment of human cancers.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 25088038 PMCID： PMC4302323 DOI： 10.2174/1568009614666140725092430

Source DB: PubMed Journal: Curr Cancer Drug Targets ISSN： 1568-0096 Impact factor: 3.428

69 in total

1. NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation.

Authors: Zaidoun Salah; Sherri Cohen; Ella Itzhaki; Rami I Aqeilan
Journal: Cell Cycle Date: 2013-10-07 Impact factor: 4.534

Review 2. Targeted inhibition of VEGF receptor 2: an update on ramucirumab.

Authors: Jeffrey Melson Clarke; Herbert I Hurwitz
Journal: Expert Opin Biol Ther Date: 2013-06-26 Impact factor: 4.388

Review 3. Mammalian HECT ubiquitin-protein ligases: biological and pathophysiological aspects.

Authors: Martin Scheffner; Sharad Kumar
Journal: Biochim Biophys Acta Date: 2013-03-29

4. Subtle gait abnormalities in Nedd4 heterozygous mice.

Authors: Daria Camera; Natasha A Boase; Sharad Kumar; David V Pow; Philip Poronnik
Journal: Behav Brain Res Date: 2013-11-23 Impact factor: 3.332

Review 5. Beclin-1: autophagic regulator and therapeutic target in cancer.

Authors: Lei-lei Fu; Yan Cheng; Bo Liu
Journal: Int J Biochem Cell Biol Date: 2013-02-16 Impact factor: 5.085

6. p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN.

Authors: S-W Hong; J-H Moon; J-S Kim; J-S Shin; K-A Jung; W-K Lee; S-Y Jeong; J J Hwang; S-J Lee; Y-A Suh; I Kim; K-Y Nam; S Han; J E Kim; K-P Kim; Y S Hong; J-L Lee; W-J Lee; E K Choi; J S Lee; D-H Jin; T W Kim
Journal: Cell Death Differ Date: 2013-10-18 Impact factor: 15.828

7. Oncogenic function of p34SEI-1 via NEDD4‑1‑mediated PTEN ubiquitination/degradation and activation of the PI3K/AKT pathway.

Authors: Samil Jung; Chengping Li; Dongjun Jeong; Soonduck Lee; Jiyeon Ohk; Meeyoung Park; Songyi Han; Jingjing Duan; Changjin Kim; Young Yang; Keun-Il Kim; Jong-Seok Lim; Young-Sook Kang; Myeong-Sok Lee
Journal: Int J Oncol Date: 2013-08-20 Impact factor: 5.650

8. NEDD4L is downregulated in colorectal cancer and inhibits canonical WNT signaling.

Authors: Jarred P Tanksley; Xi Chen; Robert J Coffey
Journal: PLoS One Date: 2013-11-28 Impact factor: 3.240

Review 9. AKT kinase pathway: a leading target in cancer research.

Authors: Ambuj Kumar; Vidya Rajendran; Rao Sethumadhavan; Rituraj Purohit
Journal: ScientificWorldJournal Date: 2013-11-13

Review 10. IGF-1R as an anti-cancer target--trials and tribulations.

Authors: Helen X Chen; Elad Sharon
Journal: Chin J Cancer Date: 2013-04-19

21 in total

Review 1. ITCH as a potential therapeutic target in human cancers.

Authors: Qing Yin; Clayton J Wyatt; Tao Han; Keiran S M Smalley; Lixin Wan
Journal: Semin Cancer Biol Date: 2020-03-10 Impact factor: 15.707

2. NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.

Authors: Laurence Booth; Jane L Roberts; Andrew Poklepovic; Paul Dent
Journal: Oncol Signal Date: 2017-08-16

3. NEDD4 is involved in acquisition of epithelial-mesenchymal transition in cisplatin-resistant nasopharyngeal carcinoma cells.

Authors: Shaoyan Feng; Guangwei Yang; Haidi Yang; Zibin Liang; Rongkai Zhang; Yunping Fan; Gehua Zhang
Journal: Cell Cycle Date: 2017-04-05 Impact factor: 4.534

NEDD4: a promising target for cancer therapy.

1. NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation.

Review 2. Targeted inhibition of VEGF receptor 2: an update on ramucirumab.

Review 3. Mammalian HECT ubiquitin-protein ligases: biological and pathophysiological aspects.

4. Subtle gait abnormalities in Nedd4 heterozygous mice.

Review 5. Beclin-1: autophagic regulator and therapeutic target in cancer.

6. p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN.

7. Oncogenic function of p34SEI-1 via NEDD4‑1‑mediated PTEN ubiquitination/degradation and activation of the PI3K/AKT pathway.

8. NEDD4L is downregulated in colorectal cancer and inhibits canonical WNT signaling.

Review 9. AKT kinase pathway: a leading target in cancer research.

Review 10. IGF-1R as an anti-cancer target--trials and tribulations.

Review 1. ITCH as a potential therapeutic target in human cancers.

2. NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.

3. NEDD4 is involved in acquisition of epithelial-mesenchymal transition in cisplatin-resistant nasopharyngeal carcinoma cells.

Review 4. NEDD4: The founding member of a family of ubiquitin-protein ligases.

5. Novel SS18-NEDD4 gene fusion in a primary renal synovial sarcoma.

6. Inhibition of NEDD4 inhibits cell growth and invasion and induces cell apoptosis in bladder cancer cells.

Review 7. Targeting the ubiquitin pathway for cancer treatment.

8. NEDD4 promotes cell growth and motility in hepatocellular carcinoma.

Review 9. HECT E3 ubiquitin ligases - emerging insights into their biological roles and disease relevance.

Review 10. Impact of posttranslational modifications in pancreatic carcinogenesis and treatments.